Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma.
Maki YoshinoHiroki IshiharaYuki NemotoShinsuke MizoguchiTakashi IkedaTakayuki NakayamaHironori FukudaKazuhiko YoshidaJunpei IizukaHiroaki ShimmuraYasunobu HashimotoTsunenori KondoToshio TakagiPublished in: Targeted oncology (2024)
Glucocorticoid administration did not negatively impact the effectiveness of ICI combination therapy for RCC, prompting glucocorticoid treatment use when AEs develop.